FDA Approves Eli Lilly's Once-Weekly Insulin Onswik for Type 2 Diabetes

Eli Lilly said Thursday that the U.S. Food and Drug Administration has approved Onswik, its once-weekly basal insulin, for adults with type 2 diabetes, to be used alongside diet and exercise to control high blood sugar, according to a Seeking Alpha Market News report. The clearance makes Onswik, whose active substance is insulin efsitora alfa, the second once-weekly basal insulin approved in the U.S., arriving roughly six months after the FDA cleared Novo Nordisk's rival product on March 26, 2026, according to a Novo Nordisk press release.

What the U.S. approval covers

Lilly's approval is for adults with type 2 diabetes as an adjunct to diet and exercise to help control blood sugar, per the company's Thursday announcement cited by Seeking Alpha. Onswik's active ingredient, insulin efsitora alfa, is described by the European Medicines Agency as a long-acting basal insulin analogue whose primary activity is regulating glucose metabolism, according to the EMA's product page and The Pharma Letter.

The U.S. decision follows earlier regulatory action in Europe. The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion on June 25, 2026, recommending marketing authorization for Onswik in type 2 diabetes, according to the EMA and reporting from Citeline. The EMA states the full EU indication is treatment of type 2 diabetes mellitus in adults, and that the most common side effect with Onswik is hypoglycemia. In Europe, the EMA says Onswik will be available as a 500 unit/mL and 1000 unit/mL solution in a pre-filled pen.

The QWINT trial data behind the drug

Across the QWINT 1-4 Phase 3 randomized, active-controlled trials, once-weekly insulin efsitora achieved HbA1c reductions comparable to once-daily basal insulin, with differences versus comparators ranging from -0.01% to -0.09% in insulin-naive and insulin-experienced populations, according to the EMA. In QWINT-1, which enrolled 795 adults who had not previously used insulin, HbA1c fell by 1.19 percentage points with weekly efsitora compared with 1.16 percentage points with daily insulin glargine, a report from Global Healthcare Magazine said. By our calculation, that is a difference of 0.03 percentage points, or about 2.6% in relative terms (1.19 minus 1.16, divided by 1.16). Global Healthcare Magazine reported that the trial demonstrated non-inferiority — meaning efsitora was shown not to be meaningfully worse than the comparator for blood glucose control, rather than superior — and that clinically significant or severe hypoglycemia occurred less frequently with efsitora in that study.

QWINT-3 and QWINT-4 similarly found weekly efsitora delivered glucose control comparable to daily insulin degludec and insulin glargine in different patient groups, though the UK's National Institute for Health and Care Excellence noted some groups most likely to benefit were underrepresented in the trials, Global Healthcare Magazine reported. NICE separately said weekly dosing could cut injections for patients switching from a daily basal insulin regimen from 365 to 52 a year, an approximately 85% reduction, according to the same report.

A market Novo Nordisk got to first

Onswik is not the first once-weekly basal insulin cleared in the U.S. The FDA approved Novo Nordisk's Awiqli (insulin icodec-abae) injection 700 units/mL on March 26, 2026, as an adjunct to diet and exercise for adults with type 2 diabetes, according to a Novo Nordisk press release and confirmed by Medscape. Novo Nordisk's path to that approval was not smooth: the FDA issued a complete response letter in July 2024 to an earlier icodec application covering both major diabetes types, partly over hypoglycemia risk in type 1 diabetes, after a May 2024 advisory panel voted against use in type 1 diabetes while raising no safety concerns for type 2, Medscape reported.

Bottom line: Onswik enters the U.S. market as the second approved once-weekly basal insulin for adults with type 2 diabetes, behind Novo Nordisk's Awiqli, which Novo said would be available nationwide "in the coming months" following its March 2026 clearance, per the company's press release. The trial record cited by regulators points to comparable glucose control rather than superiority over daily insulin, so the practical differentiator is dosing convenience: NICE estimated weekly dosing could cut injections from 365 to 52 a year for patients switching from a daily basal regimen, and its cost analysis suggested Onswik's overall cost could be similar to or lower than basal insulin given once or twice daily, Global Healthcare Magazine reported. Interpretation: on the attributed evidence above, adoption is likely to hinge on pricing, coverage and hypoglycemia management rather than on incremental HbA1c gains; neither U.S. pricing nor Lilly's launch timing was disclosed in the cited reporting.